 | | Vol. 12.41- 19 October, 2021 |
| |
|
|
| MB1-47 treatment in T cell acute lymphoblastic leukemia cells robustly inhibited cell proliferation via both cytostatic and cytotoxic effects as a result of compromised mitochondrial energy and metabolite depletion, which severely impaired nucleotide biosynthesis.
[Blood] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that transcriptional downregulation of PU.1 was an active process involving an alternative promoter in intron 3 that was induced by RUNX transcription factors driving noncoding antisense transcription.
[Blood] |
|
|
|
| Investigators reported that TET2 mutations are associated with DNA hypermethylation at enhancer sites in whole blood in clonal hematopoiesis of indeterminate potential and in both granulocytes and mononuclear cells in clonal cytopenia of undetermined significance.
[Nature Communications] |
|
|
|
| The authors employed HSCs, multipotent progenitor cells, common myeloid progenitor cells, megakaryocyte-erythroid progenitor cells, and erythroblasts from human cord blood as an erythroid differentiation model and explored the coordinated regulatory functions of lncRNAs and chromatin accessibility by integrating RNA-Seq and ATAC-Seq data.
[Blood Advances] |
|
|
|
| Researchers performed high-throughput screening and identified that oridonin, an ent-kaurene diterpenoid extracted from the Chinese herb Rabdosia rubescens, inhibited DNMT3A R882 mutant leukemic cells at a low-micromolar concentration.
[Cell Death Discovery] |
|
|
|
| Investigators profiled end-induction plasma, marrow, and cerebrospinal fluid (CSF) from ten children with b-cell acute lymphoblastic leukemia using liquid chromatography-mass spectrometry.
[Scientific Reports] |
|
|
|
| In Hemoglobin H-Constant Spring disease (HbH-CS), most genes were hypo-methylated. This included BCL2A1, which may have played an important role in the process of red blood cell differentiation and development of HbH-CS.
[Scientific Reports] |
| |
|
|
| The combination of venetoclax and azacitidine has resulted in high response rates in the upfront treatment of acute myeloid leukemia (AML) in patients aged under 75 and patients unfit for intensive chemotherapy. The authors reported outcomes of stem cell transplant-eligible patients treated at their center.
[Bone Marrow Transplantation] |
|
|
|
| The authors reported on all 17 patients with BPDCN who underwent allogeneic hematopoietic cell transplantation (allo-HCT) at their center between 2000 and 2020, and concluded that allo-HCT provided long-lasting remissions in BPDCN patients, particularly when performed in complete remission.
[Bone Marrow Transplantation] |
|
|
|
| Scientists reported the long‐term safety and efficacy of the hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen in adults with Burkitt leukemia and high-grade B-cell lymphoma, and focused on its efficacy to prevent CNS relapse.
[Blood Advances] |
|
|
|
| 43 patients received hematopoietic stem cell transplantation (HSCT) in first remission including 38 patients receiving protocol-specified HSCT where conditioning consisted of individualized targeted doses of busulfan, etoposide, and cyclophosphamide.
[Blood Advances] |
|
 |
|
|
|
| Investigators outline the current state of BH3-mimetic drugs targeting various prosurvival BCL-2 family proteins and discuss emerging data regarding primary and acquired resistance to these agents and approaches that may overcome this.
[Nature Reviews Cancer] |
|
|
|
| The authors provide a detailed summary of what is known about the impact of obesity on the pathogenesis of multiple myeloma (MM), its influence on outcomes in MM patients, and discuss potential mechanisms through which obesity is postulated to influence MM risk and prognosis.
[Leukemia] |
|
|
|
| The authors take a look at the latest advances in the use of chitosan in the treatment and improvement of leukemia.
[Cancer Cell International] |
|
|
|
|
| Geron Corporation announced the completion of patient enrollment in the IMerge Phase III clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes.
[Nature Reviews Materials] |
|
|
|
| LAVA Therapeutics N.V. announced that the US FDA has granted orphan drug designation for the company’s CD1d targeted GammabodyTM, LAVA-051, for the treatment of chronic lymphocytic leukemia.
[LAVA Therapeutics N.V.] |
|
|
|
|
| November 10 – 19, 2021
Virtual |
|
|
|
|
|
| | Boston Children’s Hospital – Boston, Massachusetts, United States |
|
|
|
| | University of Manitoba – Winnipeg, Manitoba, Canada |
|
|
|
| | The University of Kansas – Kansas City, Kansas, United States |
|
|
|
| | The University of New Mexico – Albuquerque, New Mexico, United States |
|
|
|
| | Moores Cancer Center, UC San Diego – San Diego, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
